Lyon: Reiterates Hanson Pharmaceuticals' (03692) “Outperform the Market” rating target price increase to HK$43.7

The Zhitong Finance App learned that Lyon released a research report saying that Hanson Pharmaceuticals (03692)'s performance in the first half of the year beat expectations, with revenue up 12% year on year. Despite the severe regulatory environment, reporting/basic net profit (excluding one-time income) increased 36%/19% year on year, respectively. Management reaffirmed the 2026 double-digit revenue growth guide, covering product sales and BD revenue. The bank remains optimistic about the company's global expansion and the new product cycle after 2027, raised the target price from HK$42 to HK$43.7, and reaffirmed the “outperforming the market” rating.